Nonalcoholic Steatohepatitis Clinical Trial
Official title:
Development of Non-invasive Magnetic Resonance Imaging Diagnostic Method for Nonalcoholic Steatohepatitis(NASH)
1. To evaluate feasibility of using multiparametric Magnetic resonance(MR) imaging to
predict nonalcoholic steatohepatitis(NASH)
2. To develop non-invasive diagnosis tool using multiparametric Magnetic resonance(MR)
imaging for nonalcoholic steatohepatitis(NASH)
Nonalcoholic steatohepatitis(NASH) is a severe form of nonalcoholic fatty liver
disease(NAFLD). The causes are known to be associated with metabolic diseases such as
obesity, insulin resistance type 2 diabetes, and hypercholesterolemia. Histologically, it is
characterized by steatosis, hepatocellular injury, and inflammation and fibrosis of the liver
parenchyma. Nonalcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular
carcinoma(HCC) may develop even in patients without viral hepatitis, therefore there have
been much interest and many researches in causation and diagnosis for nonalcoholic
steatohepatitis(NASH).
Liver biopsy remains the gold standard for the diagnosis of nonalcoholic fatty liver
disease(NAFLD) and is the only reliable method for differentiating nonalcoholic
steatohepatitis(NASH) from simple steatosis. However, liver biopsy has several drawbacks,
including invasiveness, potential complications such as excessive bleeding and death,
sampling error, and inter- and intra-observer variability.
Magnetic resonance(MR) imaging has been used as a multiparametric imaging tool with which to
evaluate steatosis by chemical shift imaging andm magnetic resonance(MR) spectroscopy, and
fibrosis by magnetic resonance(MR) elastography and T1 mapping. To the best of our knowledge,
there is no accurate imaging diagnostic tool for nonalcoholic steatohepatitis(NASH),
therefore the investigators aimed to develop non-invasive imaging diagnostic model using
multiparametric magnetic resonance imager(MRI).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
| Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
| Completed |
NCT02654977 -
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
|
Phase 2 | |
| Recruiting |
NCT05211284 -
Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US
|
Phase 2 | |
| Completed |
NCT02421094 -
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
|
Phase 2 | |
| Completed |
NCT01205087 -
Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome
|
Phase 2 | |
| Recruiting |
NCT00152711 -
Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis
|
N/A | |
| Completed |
NCT02217475 -
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
|
Phase 2 | |
| Completed |
NCT04031729 -
Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT03674476 -
An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function
|
Phase 1 | |
| Recruiting |
NCT03725631 -
Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD
|
N/A | |
| Terminated |
NCT04565717 -
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 1 | |
| Completed |
NCT01679197 -
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
|
Phase 2 | |
| Active, not recruiting |
NCT05084404 -
Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
|
Phase 2 | |
| Active, not recruiting |
NCT02574325 -
A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis
|
Phase 2 | |
| Terminated |
NCT00878592 -
Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity
|
N/A | |
| Recruiting |
NCT02148471 -
Fatty Acids, Genes and Microbiota in Fatty Liver
|
N/A | |
| Completed |
NCT00227110 -
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
|
Phase 4 | |
| Completed |
NCT03656744 -
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
|
Phase 2 | |
| Completed |
NCT03068078 -
A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes
|
N/A |